In June 2023 the European patent landscape will see one of the most dramatic changes in decades with the introduction of the Unitary Patent (UP) and the opening of Unified Patent Court (UPC). In a short series this blog will go through the main characteristics of the system and decisions that need to made to…

In two decisions rendered on January 11, 2023, the French Supreme Court (“Cour de cassation”) ruled for the third time in almost 50 years on the patentability of computer-implemented inventions. As we will see, in doing so the Supreme Court seems to follow the “Hitachi” approach used at the European Patent Office in this field….

The story of the creation of the Unitary Patent and the Unified Patent Court was like the game ‘Fortunately, unfortunately’, according to Pierre Véron. The French patent litigation specialist was the founder and first president of the European Patent Lawyers Association (from 2001) and has been involved in the creation of the Unitary Patent Package…

Damages enquiries in patent cases rarely make it to trial, let alone to the Court of Appeal, so this judgment provides important guidance on the assessment of damages for patent (and by extension other IP rights) infringement.   Background Anan Kasei is the proprietor of a patent to high surface area cerium oxide, a catalyst…

In June 2023 the European patent landscape will see one of the most dramatic changes in decades with the introduction of the Unitary Patent (UP) and the opening of Unified Patent Court (UPC). In a short series this blog will go through the main characteristics of the system and decisions that need to made to…

On 6 January 2023, the Danish Maritime and Commercial High Court dismissed an application for remission to the Board of Appeal of the registration of a utility model. The court considered whether the Danish Patent and Trademark Office ought to have considered a prior registration when examining ex officio a utility model application. On 14…

The new and noteworthy decision T 670/20 by Technical Board of Appeal 3.3.07 provides more legal certainty for patentees of formulation patents. The proprietors of pharmaceutical formulation and pharmaceutical use patents do often not have it easy, if and when – as is often the case – they have conducted clinical trials before the priority…